• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden.

作者信息

Yilmaz Musa, Daver Naval, Borthakur Gautam, Kadia Tapan, DiNardo Courtney, Kanagal-Shamanna Rashmi, Loghavi Sanam, Oran Betul, Popat Uday R, Pierce Sherry, Jabbour Elias, Short Nicholas J, Issa Ghayas, Ohanian Maro, Konopleva Marina, Patel Keyur, Kantarjian Hagop, Ravandi Farhad

机构信息

The Department of Leukemia, MD Anderson Cancer Center, Houston, Texas, USA.

The Department of Hematopathology, MD Anderson Cancer Center, Houston, Texas, USA.

出版信息

Am J Hematol. 2021 Aug 1;96(8):E275-E279. doi: 10.1002/ajh.26202. Epub 2021 May 8.

DOI:10.1002/ajh.26202
PMID:33891709
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9154045/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd8f/9154045/9143e6273c52/nihms-1795671-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd8f/9154045/9143e6273c52/nihms-1795671-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd8f/9154045/9143e6273c52/nihms-1795671-f0001.jpg

相似文献

1
FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden.基于FLT3抑制剂的诱导治疗及完全缓解1期的异基因干细胞移植可改善新诊断的FLT3等位基因负担极低的急性髓系白血病患者的预后。
Am J Hematol. 2021 Aug 1;96(8):E275-E279. doi: 10.1002/ajh.26202. Epub 2021 May 8.
2
Time-to-Event Ratio to Predict Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation?用于预测接受异基因造血细胞移植的急性髓系白血病患者预后的事件发生时间比？
Biol Blood Marrow Transplant. 2017 Oct;23(10):1804-1808. doi: 10.1016/j.bbmt.2017.06.016. Epub 2017 Jul 5.
3
Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.急性髓系白血病患者移植前化疗后的血液学恢复不影响异基因造血细胞移植后的生存。
Biol Blood Marrow Transplant. 2015 Aug;21(8):1425-30. doi: 10.1016/j.bbmt.2015.03.022. Epub 2015 Mar 31.
4
Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens.首次完全缓解的急性髓系白血病患者接受减低强度预处理异基因造血干细胞移植后的结局：两种方案的比较
Bone Marrow Transplant. 2008 Nov;42(10):689-91. doi: 10.1038/bmt.2008.231. Epub 2008 Aug 4.
5
Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.在原发性诱导失败或首次复发后进行挽救性异体干细胞移植的 141 例核型正常的急性髓细胞白血病患者中，分子亚群对预后的影响。
Haematologica. 2013 Apr;98(4):518-25. doi: 10.3324/haematol.2012.070235. Epub 2012 Sep 14.
6
Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia.首次完全缓解时进行异基因造血细胞移植对急性髓系白血病复发后完全缓解率及生存率的影响。
Haematologica. 2015 Jul;100(7):e254-6. doi: 10.3324/haematol.2014.118570. Epub 2015 Mar 20.
7
Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.老年急性髓系白血病患者的强化化疗及减低强度异基因造血干细胞移植
Asia Pac J Clin Oncol. 2014 Sep;10(3):246-54. doi: 10.1111/ajco.12188. Epub 2014 Mar 27.
8
Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia.与初发急性髓系白血病相比，继发急性髓系白血病在第一次完全缓解时行allo-SCT 的预后较差。
Blood Cancer J. 2020 Mar 3;10(3):26. doi: 10.1038/s41408-020-0296-3.
9
Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.在基于 BU 的清髓性造血干细胞移植中，未处理的单倍体相合、匹配的无关供体和匹配的同胞供体在完全缓解的中危和高危急性髓系白血病中的结果相当：一项单中心研究。
Ann Hematol. 2021 Jun;100(6):1579-1591. doi: 10.1007/s00277-020-04355-1. Epub 2020 Nov 24.
10
Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.急性髓系白血病的全强度和降低强度异基因干细胞移植
Bone Marrow Transplant. 2008 Mar;41(5):415-23. doi: 10.1038/sj.bmt.1705975. Epub 2008 Jan 21.

引用本文的文献

1
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors.老年 FLT3 突变型 AML 的治疗：新兴范式和一线 FLT3 抑制剂的作用。
Blood Cancer J. 2023 Sep 11;13(1):142. doi: 10.1038/s41408-023-00911-w.
2
A review of FLT3 inhibitors in acute myeloid leukemia.FLT3 抑制剂在急性髓系白血病中的研究进展。
Blood Rev. 2022 Mar;52:100905. doi: 10.1016/j.blre.2021.100905. Epub 2021 Nov 3.

本文引用的文献

1
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.2017 年欧洲白血病网络定义的 NPM1/FLT3-ITD 基因型对急性髓系白血病患者的影响。
Blood. 2020 Jan 30;135(5):371-380. doi: 10.1182/blood.2019002697.
2
Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.吉特替尼与化疗用于治疗复发/难治性 - 突变型 AML。
N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.
3
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
米哚妥林联合化疗治疗伴有FLT3突变的急性髓系白血病
N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.
4
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
5
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.急性髓系白血病（AML）患者中FLT3内部串联重复序列的存在为细胞遗传学风险分组及对首个化疗周期的反应增添了重要的预后信息：对来自英国医学研究委员会AML 10和12试验的854例患者的分析
Blood. 2001 Sep 15;98(6):1752-9. doi: 10.1182/blood.v98.6.1752.